Skip to main content

Advertisement

Table 1 Clinical and pathological data of the patients enrolled in the study

From: Expression of miR-296-5p as predictive marker for radiotherapy resistance in early-stage laryngeal carcinoma

  Number of cases (%) Radiosensitive Radioresistant X2 (p value)
n (%) n (%)
Gender
 Male 30 (88.2) 12 (40.0) 18 (60.0) 1.0
 Female 4 (11.8) 2 (50.0) 2 (50.0)
Age
 ≤60 years 16 (47.1) 5 (31.2) 11 (68.8) 0.51
 >60 years 18 (52.9) 9 (50.0) 9 (50.0)
Tobacco consumption
 Yes 31 (91.2) 14 (45.2) 17 (54.8) 0.25
 No 3 (8.8) 0 (0) 3 (100.0)
Tumor site
 Supraglottic 7 (20.6) 2 (28.6) 5 (71.4) 1.0
 Glottic 27 (79.4) 12 (44.4) 15 (55.6)
Tumor stage
 I 16 (47.1) 8 (50) 8 (50) 0.49
 II 18 (52.9) 6 (33.3) 12 (66.7)
Radiotherapy dose
 <70 Gy 10 (29.4) 5 (50.0) 5 (50.0) 0.7
 ≥70 Gy 24 (70.6) 9 (37.5) 15 (62.5)
Treatment time
 ≤55 days 20 (58.8) 9 (45.0) 11 (55.0) 0.72
 >55 days 14 (41.2) 5 (37.5) 9 (64.3)